Lv71
5008 积分 2021-05-31 加入
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
3小时前
已完结
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
6天前
已完结
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
9天前
已完结
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
11天前
已完结
Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours
11天前
已完结
Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
12天前
已关闭
Targeting the HIF2–VEGF axis in renal cell carcinoma
28天前
已完结
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial
1个月前
已完结
Neoadjuvant chemotherapy plus cadonilimab followed by extra-fascial hysterectomy for International Federation of Gynecology and Obstetrics stage IB2 cervical cancer: a prospective, multi-center, single-arm, phase 2 trial
3个月前
已关闭
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
3个月前
已关闭
皖公网安备34019202002308
